Idled since midsummer 2000, MDS Nordion's Maple 1 reactor may soon be back online. The company, which supplies most of the world's medical isotopes, has been authorized by the Canadian Nuclear Safety Commission to restart the reactor in low-power mode.
Idled since midsummer 2000, MDS Nordion's Maple 1 reactor may soon be back online. The company, which supplies most of the world's medical isotopes, has been authorized by the Canadian Nuclear Safety Commission to restart the reactor in low-power mode. Located in Chalk River near Ottawa, the reactor was taken offline in July 2000 after problems occurred during testing of its shutoff rods. When fully operational, either of the two 10-Mw Maple reactors will be able to exceed the world's current demand for molybdenum-99, iodine-131, and xenon-133.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.